Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 3Leukemia 3Neoplasms 2Multiple Myeloma 2Lymphoma 2Leukemia, Myeloid, Acute 2Immunologic Deficiency Syndromes 2Graft vs Host Disease 2Fatigue 2Breast Neoplasms 2Brain Neoplasms 2Blast Crisis 2Waldenstrom Macroglobulinemia 1Stage IA Uterine Sarcoma 1Spinal Cord Neoplasms 1Spinal Cord Compression 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Paranasal Sinus Neoplasms 1Oligodendroglioma 1Neurologic Manifestations 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Temozolomide 2Therapeutics 1Sorafenib 1Irinotecan 1Immunoglobulins 1Cytidine Triphosphate 1Bevacizumab 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neurologic Manifestations × Therapeutics × Clear all
NCT00360828 2017-03-23

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
10 enrolled 6 charts
CNS

Astrocytoma, Brain Neoplasms, Glioma, Neurologic Manifestations, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡